[1]
|
Carney, J.A. and Young, W.F. (1992) Primary pigmented nodular adrenocortical disease and its associated conditions. Endocrinologist, 2, 6-21. http://dx.doi.org/10.1097/00019616-199201000-00003
|
[2]
|
Stratakis, C.A. and Kirschner, L.S. (1998) Clinical and genetic analysis of primary bilateral adrenal diseases (micro-and macronodular disease) leading to Cushing syndrome. Hormone and Metabolic Research, 30, 456-63. http://dx.doi.org/10.1055/s-2007-978914
|
[3]
|
Stratakis, C.A., Kirschner, L.S. and Carney, J.A. (2001) Clinical and molecular features of the Carney complex: Diagnostic criteria and recommendations for patient evaluation. The Journal of Clinical Endocrinology & Metabolism, 86, 4041-4046. http://dx.doi.org/10.1210/jc.86.9.4041
|
[4]
|
Groussin, L., Horvath, A., Jullian, E., Boikos, S., Rene-Corail, F., Lefebvre, H., et al. (2006) A PRKAR1A mutation associated with primary pigmented nodular adrenocortical disease in 12 kindreds. The Journal of Clinical Endocrinology & Metabolism, 91, 1943-1949. http://dx.doi.org/10.1210/jc.2005-2708
|
[5]
|
Arnaldi, G., Angeli, A., Atkinson, A.B., et al. (2003) Diagnosis and complications of Cushing’s sy ndrome: A consensus statement. The Journal of Clinical Endocrinology & Metabolism, 88, 5593-5602. http://dx.doi.org/10.1210/jc.2003-030871
|
[6]
|
Stratakis, C.A. (2007) Adrenocortical tumors, primary pigmented adrenocortical disease (PPNAD)/Carney complex, and other bilateral hyperplasias: The NIH studies. Hormone and Metabolic Research, 39, 467-473. http://dx.doi.org/10.1055/s-2007-981477
|
[7]
|
Carney, J.A., Gordon, H., Carpenter, P.C., Shenoy, B.V. and Go, V.L. (1985) The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine, 64, 270-283. http://dx.doi.org/10.1097/00005792-198507000-00007
|
[8]
|
Sarlis, N.J., Chrousos, G.P., Doppman, J.L., Carney, J.A. and Stratakis, C.A. (1997) Primary pigmented nodular adrenocortical disease: Reevaluation of a patient with Carney complex 27 years after unilateral adrenalectomy. The Journal of Clinical Endocrinology & Metabolism, 82, 1274-1278. http://dx.doi.org/10.1210/jc.82.4.1274
|
[9]
|
Groussin, L., Jullian, E., Perlemoine, K., Louvel, A., Leheup, B., Luton, J.P., et al. (2002) Mutations of the PRKAR1A gene in Cushing’s syndrome due to sporadic primary pigmented adrenocortical disease. The Journal of Clinical Endocrinology & Metabolism, 87, 4324-4329. http://dx.doi.org/10.1210/jc.2002-020592
|
[10]
|
Doppman, J.L., Travis, W.D., Nieman, L., Chrousos, G.P., Gomez, M.T., Cutler, G.B., et al. (1989) Cushing syndrome due to primary pigmented nodular adrenocortical disease: Findings at CT and MR imaging. Radiology, 172, 415-420.
|
[11]
|
Stratakis, C.A., Sarlis, N., Kirschner, L.S., Carney, J.A., Doppman, J.L., Nieman, L.K., Chrousos, G.P. and Papanicolaou, D.A. (1999) Paradoxical response to dexamethasone in the diagnosis of primary pigmented nodular adrenocortical disease. Annals of Internal Medicine, 131, 585-591. http://dx.doi.org/10.7326/0003-4819-131-8-199910190-00006
|
[12]
|
Neville, A.M., McGee, J.O’D., Isaacson, P.G. and Wright, N.A. (1992) Oxford Textbook of pathology. Vol. 2b. In: Pathology of systems. Oxford medical publications. Oxford University Press, New York, 1968-1986.
|